Spots Global Cancer Trial Database for Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Official Title: A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
Study ID: NCT01954992
Conditions
Study Description
Brief Summary: The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Innovative Clinical Research Institute, Whittier, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Gabrail Cancer Center Research, Canton, Ohio, United States
Contact Details
Name: Edwin Thomas
Affiliation: Eleison Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
